{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:05:50Z","timestamp":1791353150996,"version":"4.3.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"SI2","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this study was to evaluate the efficacy and safety of MMF in juvenile idiopathic inflammatory myopathies (JIIMs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients diagnosed with JIIM and treated with MMF enrolled in the Juvenile Dermatomyositis Research Group (JDRG) in the UK or followed at the Giannina Gaslini Institute in Genoa, Italy, were included. The following information was collected retrospectively at MMF initiation, at 3, 6 and 12\u2009months after treatment start, and at last follow-up visit: clinical manifestations, laboratory data, physicians\u2019 subjective assessment of disease activity, standardized outcome measures of muscle strength\/endurance, cutaneous disease activity, physical function, global disease activity, cumulative damage, and ongoing treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 29 patients included, 23 had juvenile DM and 6 had overlap myositis. During administration of MMF, improvement in measures of muscle strength, skin disease activity, and overall disease activity was seen, with an increase in the frequency of normal scores for Manual Muscle Test-8 from 50.0% to 83.3%, Childhood Myositis Activity Score from 53.5% to 88.9%, muscle component of DAS from 55.2% to 84.2%, skin component of DAS from 31.0% to 42.1%, visual analogue scale for skin disease activity from 25.0% to 47.4%, and visual analogue scale for overall disease activity from 7.1% to 42.1%. The number of patients with inactive disease increased from 10.3% at baseline to 68.5% at last follow-up. CS dose was significantly reduced, from 0.3 to 0.1\u2009mg\/kg\/day. No relevant side effects were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our experience suggests that MMF is a valuable therapeutic option for the management of JIIM.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keac404","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T13:46:07Z","timestamp":1659707167000},"page":"SI163-SI169","source":"Crossref","is-referenced-by-count":15,"title":["Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0261-5960","authenticated-orcid":false,"given":"Giulia Camilla","family":"Varnier","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli Studi di Genova , Genoa, Italy"},{"name":"Paediatric Rheumatology, Royal Manchester Children\u2019s Hospital , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Consolaro","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Genova , Genoa, Italy"},{"name":"Clinica Pediatrica e Reumatologica, IRCCS Istituto Giannina Gaslini , Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iek Leng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology, Great Ormond Street Hospital , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Silva Riveiro","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Genova , Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Pilkington","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology, Great Ormond Street Hospital , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Genova , Genoa, Italy"},{"name":"Clinica Pediatrica e Reumatologica, IRCCS Istituto Giannina Gaslini , Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.rdc.2013.06.001","article-title":"Classification and treatment of the juvenile Idiopathic Inflammatory Myopathies","volume":"39","author":"Rider","year":"2013","journal-title":"Rheum Dis Clin N Am"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.12444","article-title":"The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes and outcomes","volume":"280","author":"Rider","year":"2016","journal-title":"J Intern Med"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.berh.2009.07.007","article-title":"Juvenile dermatomyositis: new development in pathogenesis, assessment and treatment","volume":"23","author":"Wedderburn","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1002\/art.23035","article-title":"Type 1 interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus","volume":"56","author":"Lee","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleuchin-6 and type 1 interferon\u2013regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","article-title":"Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood","volume":"371","author":"Feldman","year":"2008","journal-title":"Lancet"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/acr.20015","article-title":"Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicentre study of 490 patients","volume":"62","author":"Ravelli","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1529-8019.2007.00136.x","article-title":"Mycophenolate mofetil","volume":"20","author":"Zwerner","year":"2007","journal-title":"Dermatol Ther"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanism of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/0961203308098631","article-title":"Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study","volume":"18","author":"Roland","year":"2009","journal-title":"Lupus"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/0961203308094999","article-title":"Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicentre study","volume":"18","author":"Falcini","year":"2009","journal-title":"Lupus"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.autrev.2006.11.001","article-title":"Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases?","volume":"6","author":"Iaccarino","year":"2007","journal-title":"Autoimmun Rev"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody\u2013associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/acr.20269","article-title":"Mycophenolate mofetil, a possible therapeutic agent for children with juvenile dermatomyositis","volume":"62","author":"Rouster-Stevens","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00296-010-1653-5","article-title":"Mycophenolate mofetil in juvenile dermatomyositis: a case series","volume":"32","author":"Dagher","year":"2012","journal-title":"Rheumatol Int"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Bellutti Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acr.20695","article-title":"Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference","volume":"64","author":"Huber","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023022318581915300_","volume-title":"Muscles: testing and function","author":"Kendall","year":"1993","edition":"4th edn"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1002\/1529-0131(199910)42:10<2213::AID-ANR25>3.0.CO;2-8","article-title":"Development of validated disease activity and damage indices for the juvenile idiopathic in\ufb02ammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function","volume":"42","author":"Lovell","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/art.10924","article-title":"Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence","volume":"49","author":"Bode","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic in\ufb02ammatory myopathies: development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.1780371209","article-title":"Measurement of health status in children with juvenile rheumatoid arthritis","volume":"37","author":"Singh","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2023022318581915300_","first-page":"S1","article-title":"Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries: review of the general methodology","volume":"19(Suppl 23)","author":"Ruperto","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dmcn.14020","article-title":"Mycophenolate mofetil in paediatric autoimmune or immune-mediated diseases of the central nervous system: clinical experience and recommendations","volume":"61","author":"Nosadini","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/rheumatology\/kel336","article-title":"Mycophenolate mofetil treatment in resistant myositis","volume":"46","author":"Pisoni","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.wnl.0000208416.32471.c0","article-title":"Mycophenolate mofetil in dermatomyositis: is it safe?","volume":"66","author":"Rowin","year":"2006","journal-title":"Neurology"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","article-title":"Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy","volume":"44","author":"Majithia","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/mus.10026","article-title":"Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome","volume":"25","author":"Schneider","year":"2002","journal-title":"Muscle Nerve"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","article-title":"Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis","volume":"9","author":"Danieli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MAJ.0b013e31818d094b","article-title":"Experience of mycophenolate mofetil in 10 patients with autoimmune related interstitial lung disease demonstrates promising effects","volume":"337","author":"Saketkoo","year":"2009","journal-title":"Am J Med Sci"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease\u2013related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease\u2013associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J Rheumatol"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/acr.20212","article-title":"Mycophenolate mofetil for interstitial lung disease in dermatomyositis","volume":"62","author":"Morganroth","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023022318581915300_","first-page":"9","article-title":"Recent treatment of interstitial lung disease with idiopathic in\ufb02ammatory myopathies","volume":"9","author":"Kawasumi","year":"2015","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10067-016-3443-2","article-title":"Mycophenolate mofetil for the patients with interstitial lung disease in amyopathic dermatomyositis with anti-MDA5 antibodies","volume":"36","author":"Hayashi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2023022318581915300_","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/art.24555","article-title":"Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy","volume":"60","author":"Niewold","year":"2009","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac404\/45296880\/keac404.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI2\/SI163\/49318779\/keac404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI2\/SI163\/49318779\/keac404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T10:10:47Z","timestamp":1700907047000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/SI2\/SI163\/6656366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":39,"journal-issue":{"issue":"SI2","published-online":{"date-parts":[[2022,8,5]]},"published-print":{"date-parts":[[2023,2,23]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac404","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,8,5]]}}}